Ascent Group LLC Sells 7,224 Shares of Aura Biosciences, Inc. $AURA

Ascent Group LLC decreased its stake in shares of Aura Biosciences, Inc. (NASDAQ:AURA) by 34.1% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 13,964 shares of the company’s stock after selling 7,224 shares during the quarter. Ascent Group LLC’s holdings in Aura Biosciences were worth $87,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the business. Harbor Capital Advisors Inc. raised its stake in Aura Biosciences by 27.2% during the second quarter. Harbor Capital Advisors Inc. now owns 32,739 shares of the company’s stock valued at $205,000 after purchasing an additional 6,998 shares in the last quarter. Acorn Capital Advisors LLC purchased a new position in Aura Biosciences in the 1st quarter worth about $3,460,000. Dynamic Technology Lab Private Ltd purchased a new position in Aura Biosciences in the 1st quarter worth about $137,000. Long Focus Capital Management LLC grew its holdings in Aura Biosciences by 30.8% during the 1st quarter. Long Focus Capital Management LLC now owns 3,319,582 shares of the company’s stock worth $19,453,000 after acquiring an additional 781,808 shares in the last quarter. Finally, Wellington Management Group LLP grew its holdings in Aura Biosciences by 6.0% during the 1st quarter. Wellington Management Group LLP now owns 138,952 shares of the company’s stock worth $814,000 after acquiring an additional 7,898 shares in the last quarter. Hedge funds and other institutional investors own 96.75% of the company’s stock.

Aura Biosciences Trading Up 5.7%

Shares of AURA stock opened at $6.09 on Thursday. The company’s 50-day moving average price is $6.40 and its 200-day moving average price is $6.18. The stock has a market cap of $378.31 million, a price-to-earnings ratio of -3.11 and a beta of 0.45. Aura Biosciences, Inc. has a twelve month low of $4.34 and a twelve month high of $12.38.

Aura Biosciences (NASDAQ:AURA) last issued its quarterly earnings data on Wednesday, August 13th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.02. As a group, equities research analysts predict that Aura Biosciences, Inc. will post -1.66 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on AURA. Zacks Research upgraded shares of Aura Biosciences from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Aura Biosciences in a research report on Wednesday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $22.00 target price on shares of Aura Biosciences in a report on Wednesday, August 13th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $22.00.

Insider Transactions at Aura Biosciences

In other Aura Biosciences news, SVP Amy Elazzouzi sold 7,722 shares of the business’s stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $6.70, for a total transaction of $51,737.40. Following the sale, the senior vice president directly owned 86,558 shares in the company, valued at $579,938.60. This represents a 8.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 6.30% of the stock is owned by company insiders.

Aura Biosciences Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.